Evaluation of prevalence of d 32 mutation in CCR5 gene in breast cancer patients in Rafsanjan city

Background and Chemokines and their receptors are expressed in different types of malignancies. CC chemokines MIP-1a (CCL3), MIP-1b (CCL4) and RANTES (CCL5) is believed to be anti-tumor and also aid to the metastasis in tumor microenvironment. CCR2 and CCR5 are special G-protein receptors for these chemokines. Due to the important role of CCR5 chemokine receptor in tumor biology, this project is designed to examine d 32 mutation in CCR5 gene regards breast cancer. This experimental study was performed during 2007-8 on 100 healthy adults and 36 breast cancer patients by Gap-PCR. The demographic information also was collected by questionner and t-test Chi-square was used for statistical analysis of data. Our results showed that none of breast cancer patients had CCR5-d 32 mutation while 3 (3%) cases of controls had heterozygotic form of this mutation. Our results showed that there is not any CCR5-d 32 mutation in patients. Therefore, it appears that this mutation don’t play any role in breast cancer.